Management of Mixed-Phenotype Acute Leukemia in the East of France

checkorphan
Learn more about:
Biphenotypic acute leukaemia
Related Clinical Trial
First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Management of Mixed-Phenotype Acute Leukemia in the East of France Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Brief Title

Management of Mixed-Phenotype Acute Leukemia in the East of France

Official Title

Management of Mixed-Phenotype Acute Leukemia in the East of France

Brief Summary

      Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is
      heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of
      France based on a 10-year multicentre retrospective collection.

Study Type

Observational

Primary Outcome

Age of the patients when diagnosed with MPAL

Secondary Outcome

 Date of every relapse for each patient

Condition

Mixed Phenotype Acute Leukemia

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

70

Start Date

September 2018

Completion Date

June 2019

Primary Completion Date

June 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Adult patients over 18 years of age

          -  Diagnosis of biphenotypic acute leukemia or mixed-phenotype acute leukemia between
             2008 and 2018

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, ,

Administrative Informations

NCT ID

NCT03599869

Organization ID

PSS2017/ELABEST-BONMATI/VS

Responsible Party

Sponsor

Study Sponsor

Central Hospital, Nancy, France

Study Sponsor

, ,

Verification Date

July 2018